Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome
- PMID: 22955358
- DOI: 10.1097/MCG.0b013e318264e918
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome
Abstract
There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in postinfectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future.
Similar articles
-
Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 2:S214-7. doi: 10.1097/MCG.0b013e31817da129. J Clin Gastroenterol. 2008. PMID: 18685517 Review.
-
Treating irritable bowel syndrome with probiotics: the evidence.Proc Nutr Soc. 2010 May;69(2):187-94. doi: 10.1017/S002966511000011X. Epub 2010 Mar 18. Proc Nutr Soc. 2010. PMID: 20236566 Review.
-
Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.Dig Dis. 2009;27 Suppl 1:115-21. doi: 10.1159/000268131. Epub 2010 Mar 4. Dig Dis. 2009. PMID: 20203507 Review.
-
Mucosal barrier defects in irritable bowel syndrome. Who left the door open?Am J Gastroenterol. 2006 Jun;101(6):1295-8. doi: 10.1111/j.1572-0241.2006.00667.x. Am J Gastroenterol. 2006. PMID: 16771952
-
The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1. J Clin Gastroenterol. 2012. PMID: 22157240 Clinical Trial.
Cited by
-
Gluten and Functional Abdominal Pain Disorders in Children.Nutrients. 2018 Oct 12;10(10):1491. doi: 10.3390/nu10101491. Nutrients. 2018. PMID: 30322070 Free PMC article. Review.
-
Lactobacillus acidophilus Induces a Strain-specific and Toll-Like Receptor 2-Dependent Enhancement of Intestinal Epithelial Tight Junction Barrier and Protection Against Intestinal Inflammation.Am J Pathol. 2021 May;191(5):872-884. doi: 10.1016/j.ajpath.2021.02.003. Epub 2021 Feb 16. Am J Pathol. 2021. PMID: 33607043 Free PMC article.
-
Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome.Biomedicines. 2020 Nov 20;8(11):519. doi: 10.3390/biomedicines8110519. Biomedicines. 2020. PMID: 33233503 Free PMC article.
-
In vitro prevention of salmonella lipopolysaccharide-induced damages in epithelial barrier function by various lactobacillus strains.Gastroenterol Res Pract. 2013;2013:973209. doi: 10.1155/2013/973209. Epub 2013 Jun 6. Gastroenterol Res Pract. 2013. PMID: 23840201 Free PMC article.
-
Clinical and Metabolomic Effects of Lactiplantibacillus plantarum and Pediococcus acidilactici in Fructose Intolerant Patients.Nutrients. 2022 Jun 15;14(12):2488. doi: 10.3390/nu14122488. Nutrients. 2022. PMID: 35745219 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources